Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs